AAV Gene Therapies: Learnings From Clinical Trials to Inform Real World Discussions

Saturday, 9 July 2022
11:30 AM – 12:45 PM BST

Add this event to your calendar:
Apple  Outlook  Google

Find out when it starts in your own time zone: click here

ICC Capital Suite 7+12 (Level 3) or virtual

COMPLIMENTARY LUNCH BOXES PROVIDED BY THE ISTH WILL BE AVAILABLE

Interested in receiving educational information from BioMarin? YES

What are key steps along the gene therapy clinical trial treatment journey for people with haemophilia?

What is the importance of liver health before and during participation in a haemophilia gene therapy clinical trial?

How can people with haemophilia be empowered to make informed choices about participation in a gene therapy clinical trial?

Faculty

Flora Peyvandi, Haematologist
Dr. Peyvandi is Professor of Internal Medicine at the University of Milan and Director of the Angelo Bianchi Bonomi Haemophilia and Thrombosis Centre, Fondazione IRCCS Ca’ Granda, Ospedale Maggiore Policlinico, Milan, Italy. In addition, she participates in clinical, educational and research activities worldwide and is a member of steering committees of international haemophilia societies. She has been involved in many clinical and medical research project focusing on the investigation of molecular mechanisms of coagulation disorders.

Brian O’Mahony, Haemophilia Patient Association Representative
Brian O’Mahony is Chief Executive of the Irish Haemophilia Society, Dublin, Ireland. He previously served as Chair of the Irish Haemophilia Society for 17 years, as President of the WFH for 10 years and President of the European Haemophilia Consortium (EHC) for 8 years. He has facilitated training courses for Health Ministers, clinicians and patient organisations in many countries. He is a medical scientist by profession and has severe haemophilia B for which he received gene therapy in a clinical trial 2 years ago.

Kate Khair, Nurse
As a state registered nurse, Dr. Khair became an advocate of the nurse’s role in the multidisciplinary team for haemophilia. She has a long standing interest in the management of severe haemophilia and has a specific interest in the nurse role in the management of severe haemophilia. In addition, she is a member of both the NHS England haemophilia and Rare Diseases research networks.

Wolfgang Miesbach, Haematologist
Prof. Dr. med. Miesbach is head of the Department of Coagulation Disorders and the Comprehensive Care Haemophilia Centre at the Goethe University Hospital in Frankfurt/Main, Germany. In addition, he is head of the EAHAD Gene Therapy Working Group and member of gene therapy GT steering committees of international societies. His main research interest is in the field of haemophilia with focus on GT and quality of the investigations.

Graham R Foster, Hepatologist
Dr. Foster is a Professor of Medicine at Queen Mary University of London and a consultant at Barts Health Trust, London, UK. He has a long standing interest in the management of chronic viral hepatitis. He is a past President of the British Association for the Study of the Liver and the current lead for the NHS England Hepatitis C Elimination programme.

Kate Khair, Nurse
As a state registered nurse, Dr. Khair became an advocate of the nurse’s role in the multidisciplinary team for haemophilia. She has a long standing interest in the management of severe haemophilia and has a specific interest in the nurse role in the management of severe haemophilia. In addition, she is a member of both the NHS England haemophilia and Rare Diseases research networks.

Brian O’Mahony, Haemophilia Patient Association Representative
Brian O’Mahony is Chief Executive of the Irish Haemophilia Society, Dublin, Ireland. He previously served as Chair of the Irish Haemophilia Society for 17 years, as President of the WFH for 10 years and President of the European Haemophilia Consortium (EHC) for 8 years. He has facilitated training courses for Health Ministers, clinicians and patient organisations in many countries. He is a medical scientist by profession and has severe haemophilia B for which he received gene therapy in a clinical trial 2 years ago.

Flora Peyvandi, Haematologist
Dr. Peyvandi is Professor of Internal Medicine at the University of Milan and Director of the Angelo Bianchi Bonomi Haemophilia and Thrombosis Centre, Fondazione IRCCS Ca’ Granda, Ospedale Maggiore Policlinico, Milan, Italy. In addition, she participates in clinical, educational and research activities worldwide and is a member of steering committees of international haemophilia societies. She has been involved in many clinical and medical research project focusing on the investigation of molecular mechanisms of coagulation disorders.

What are key steps along the gene therapy clinical trial treatment journey for people with haemophilia?

What is the importance of liver health before and during participation in a haemophilia gene therapy clinical trial?

How can people with haemophilia be empowered to make informed choices about participation in a gene therapy clinical trial?

Saturday, 9 July 2022
11:30 AM – 12:45 PM BST

Find out when it starts in your own time zone: click here

ICC Capital Suite 7+12 (Level 3) or virtual

COMPLIMENTARY LUNCH BOXES PROVIDED BY THE ISTH WILL BE AVAILABLE

Interested in receiving educational information from BioMarin? YES